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Coronary heart disease (CHD) affects 2.3 million people in the UK and is a leading cause of 
premature death1. Improvements in diagnosis and medical treatment have resulted in 
improved survival rates, however, the burden of CHD remains a major public health 
challenge. Cardiac rehabilitation (CR) is a comprehensive programme of secondary 
prevention measures that has been shown to have significant health benefits for patients 
with CHD.   
The aim of CR is to increase survival, reduce cardiovascular disease (CVD)related 
morbidity and hospital admissions, improve functional capacity, quality of life and facilitate 
early return to work2 3. This is achieved through structured exercise training and increasing 
physical activity, preventive medical therapies, education and behaviour change, counselling 
support and other cardiovascular risk factor reduction strategies2 4. Although variations in 
service provision exist across the UK5, CR exercise training is usually offered in the early 
postadmission period following a cardiac event. The UK healthcare system no longer uses 
‘Phases’ to describe CR, however, early postadmission supervised exercise training may be 
equated to Phase III CR.  
Structured exercise training is one of the primary components of CR2 6 7 and may make the 
largest contribution to increasing patient survival8 9. Exercise training alone is associated with 
a 28% allcause mortality reduction10. Contemporary evidence suggests that allcause and 
CVD mortality, recurrent cardiac events,11 and, hospital admissions are reduced whilst 
quality of life is improved9. However, a recent Cochrane review questioned these findings 
and reported that CVD mortality (10.4 to 7.6%) but not allcause mortality was reduced 
following CR9 12.  
Contradictory to consecutive meta–analyses9 11 13, UKderived data suggest that CR may not 
improve CVD or allcause mortality1416. The most recent UK randomised control study 
reported no survival benefit16, though did not consider cardiorespiratory fitness (CRF) 
changes. Peak oxygen uptake [VO2peak](determined during maximal cardiopulmonary 
exercise testing (CPET) 17 is used to quantify CRF.  VO2peak is inversely associated with all
cause and cardiovascular mortality in patients with CHD18 19. A 1% improvement in VO2peak 
following 3 months exercise training confers a 2% improvement in cardiovascular mortality20 
with the least fit patients showing the greatest survival advantage from any improvements21 
22. However, a doseresponse relationship between the amount of exercise training 
undertaken and increase in VO2peak may exist
20.  
UK clinical trial data 23 in patients who sustained a myocardial infarction (MI), reported 
increases in VO2peak following 12 months supervised exercise training compared to controls. 
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However, a recent multicentre study of routine UKbased CR (current clinical practice) 
indicates that the “exercise dose” within outpatient CR may be insufficient to meaningfully 
improve CRF24 25 (~0.5 METs; or VO2 1.75 ml
.kg1.min1) when compared to international 
programmes [~1.5 METs; or VO2 1.75 ml
.kg1.min1]26. Fewer than 50% of patients completing 
a ‘typical’ UK CR programme may achieve minimal clinically important improvements to CRF, 
(70 metres) derived from incremental shuttle walk testing27. These findings may explain why 
UK CR programmes do not appear to improve patient survival1416. However, UK studies 
typically estimate CRF changes from submaximal exercise testing protocols. This may lead 
to inaccurate reporting of VO2peak changes following CR in patients with CHD
28. There is a 
need to investigate the exercisebased CR findings of Sandercock, et al. 29 using ‘gold
standard’ CPET testing methods. 
 
Numerous mechanisms may be responsible for improving survival associated with exercise
based CR and improved CRF, including cardiovascular risk factor modification (smoking, 
lipids, blood pressure, glucose metabolism). Within one metaanalysis, approximately half of 
the 28% reduction in cardiac mortality achieved with exercisebased CR was attributed to 
reductions in major cardiovascular risk factors, particularly reduced smoking9. Anti
ischaemic/thrombotic effects, cardiac remodelling, and antiatherosclerotic and vascular 
conditioning have also been documented30 31. Larger volumes of exercise training 
(associated with higher energy expenditures) have been shown to underline regression of 
atherosclerosis32. Carotid intimamedia thickness (CIMT) is a practical, valid and reliable 
noninvasive surrogate marker of subclinical atherosclerosis3335. Carotid ultrasound has 
been used to noninvasively characterise dynamic changes in atherosclerotic plaque 
characteristics. Whilst some data suggest that exercise training may reduce CIMT in 
patients at elevated CV risk36 37, the evidence is still unclear38. Furthermore, no UK study has 
investigated the effects of a shortterm, routine CR exercise training programme on longer
term atherosclerotic disease progression. The modest improvements in CRF reported within 
UK CR patients39 40, and the reported absence of improved survival outcomes, may indicate 
that the exercise dose prescribed to patients is too low to meaningfully influence CRF, 
cardiometabolic risk factors and atherosclerotic plaque progression. Therefore, the 
objectives of this controlled trial are: 
 
To determine, when compared to CR without exercise training, the short (eightweek) and 
longerterm (12month) effects of a routine, eight week, low to moderate intensity UK CR 
exercise training programme on: 
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1. Changes in VO2peak assessed using ‘goldstandard’ cardiopulmonary exercise testing 
(CPET)  
 
2.  Subclinical and clinical atherosclerosis progression using CIMT measurements  
 
 
3. Standard risk factors including lipid profiles, blood pressure and blood glucose, 
measurement, and cardiometabolic markers including NTPro BNP and hsCRP)  
4.  
5. Estimated allcause 5year mortality risk using the comprehensive CALIBER score41)  
 
%&'"#

,	##&	
Ethical approval has been obtained from the Humber Bridge NHS Research Ethics 
Committee  Yorkshire and the Humber (12/YH/0278). Any protocol amendments will be 
submitted to the committee prior to implementation.  


()
# 

This study will be a pragmatic, singlecentre longitudinal controlled study of a routine NHS 
outpatient CR programme. Patients recruited to the study will have the option to attend a 
routine low to moderate intensity, eightweek circuitbased CR exercise training programme 
(routine CR), or voluntarily abstain (control group) from the structured exercise training 
component of the CR programme. Study measures will be made before starting exercise 
training, or approximately two weeks after recruitment for patients who decline the exercise 
programme (visit 1). Followup assessment will be conducted after completion of a patients 
CR programme (visit 2) or approximately 10 weeks after recruitment for controls. The 
difference in planned reassessment times accounts for a typical two week waiting time to 
receive NHS treatment (exercise training) and will allow both groups to be reassessed within 
a similar timeframe. Patients will also be invited for assessment 12months after visit 1 (visit 
3).    
Routine CR will be delivered by clinical (not research) staff within existing NHS secondary 
prevention care pathways. The study will be conducted in collaboration with Hull’s CR team 
(City Health Care Partnership CIC) who follow the Department of Health 42 ‘best care 
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pathway’ for referral and delivery of CR. Adherence to national guidelines on exercise 
prescription will allow broad generalisability of the findings to UKbased CR programmes. 
The trial protocol adheres to the Standard Protocol Items: Recommendations for Clinical 
Trials (SPIRIT) guidelines. 

 

Patients can attend CR at three sites across Hull; The University of Hull (West Hull), Hull 
Royal Infirmary (Hull Centre) and the Freedom Centre (Community Centre, East Hull). 
Testing will be conducted at the Academic Cardiology Research Laboratory at Castle Hill 
Hospital, Hull. 
 
*+

Patients who have had a recent hospital admission for stable angina, MI (STEMI and Non
STEMI), coronary artery bypass graft (CABG) surgery, and elective percutaneous coronary 
intervention (PCI) will be recruited recruitment by a specialist CR, typically within twoweek 
of sustaining a cardiac event.  Patients will be offered all CR secondary prevention 
components recommended by the BACPR 2, including exercise training. Those opting to 
take part in structured, supervised exercise training will be referred to as the treatment group 
(TG). Those who decline exercise training will be known as the control group (CG). Group 
randomisation was not performed as this was deemed unethical given the current evidence 
for the benefits of exercisebased CR9. Patients in both groups will be advised to increase 
unsupervised physical activity levels.  
 
General inclusion criteria 
1. Primary diagnosis of CHD including recent MI, coronary artery bypass graft CABG 
surgery, elective percutaneous coronary intervention (PCI) or exertional angina. 
2. Clinically stable patients. 
3. Aged 3085 years. 
4. Absence of contraindications to exercise testing and exercise training. 
5. Capable and mentally able to understand and follow the instructions of the health 
professional team. 
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General exclusion criteria 
1. Clinically unstable patients. 
2. Clinically significant valvular heart disease. 
3. Patients with a nonischaemic diagnosis 
4. Patients with coexisting congenital heart conditions, significant comorbidities 
including severe CHF (left ventricular ejection fraction <30%), advanced cancer and 
conditions preventing the patient from providing informed consent. 
5. Current drug abusers and excessive alcohol drinkers. 
6. Patients not freely living in the community, such as those currently serving a 
sentence with HM prison. 
7. Patients unwilling or unable to participate in key aspects of the study.  
8. Patients with ongoing clinical complications, open wounds or systemic infections. 
9. Women who are pregnant or breastfeeding. 
 
A study flow diagram is presented in Figure 1. Patients will be referred to CR via the local 
tertiary hospital (Castle Hill Hospital, Hull) where they will receive a onetoone assessment 
with a CR specialist nurse. Nursing staff will provide patients with information on cardiac 
medications, diet, smoking cessation, physical activity, structured exercise training and other 
secondary prevention measures. Eligible patients’ will be offered the opportunity to 
participate in this study. Group specific patient information sheets will be provided.  
Written informed consent will be obtained by a medical doctor at the Academic Cardiology 
Research Laboratory, Castle Hill Hospital, Hull. Patients will be asked to attend in a 
euhydrated state and having not conducted strenuous exercise within the previous 24 hours. 
Patients will not fast prior to any visit due to the need to conduct maximal CPET at the end of 
the fourhour visit. Patients will be advised to eat a light meal prior to each visit.  
A resting ECG, echocardiogram, venepuncture, carotid ultrasound (CIMT) and dual Xray 
absorptiometry [DXA] at each visit. A CPET to volitional exhaustion or clinicallyrelevant 
symptoms43 will be conducted after all other investigations have been completed. Patients 
will then follow their chosen treatment plan (treatment or control).  All measurements taken 
at visit 1 will be repeated at visit 2 and 3. At visit 2 and 3, all patients will be asked to verbally 
report the typical number of structured exercise sessions they engaged in during the 
previous week, as well as how many minutes each of those session lasted. This will allow a 
comparison of exercise dose between both groups. Adverse events will be reported in 
accordance with NHS good clinical practice guidelines. 
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Patients will be instructed to remove footwear, jackets and items from their pockets prior to 
standing in the centre of the scales. Body mass (Kg) will be measured using a Tanita Body 
Composition Analyser MC – 180MA (Tanita, Amsterdam, The Netherlands) and recorded to 
one decimal place. Stature (cm) will be measured (Leicester Height Measure, SECA, 
Birmingham, United Kingdom) with patients positioned in the Frankfort plane with their heels 
and head positioned to the back of the stadiometer. The highest measurement recorded 
during a single full inbreath will be taken as the individual’s height. Body mass index (BMI) 
will reported as kg.m2, where kg is a patients’ body mass and m2 is height squared. 
A single waist and hip circumference measurements will be taken 1 cm above the iliac crest, 
and from the widest aspect of the buttocks using an inflexible tape.  Both measurements will 
be recorded in cm and the waisttohip circumference ratio (waist/hip) will be reported44. 
Patients will rest for 15 minutes in a semisupine position on an examination bed. A 12lead 
ECG (GE Healthcare, Buckinghamshire, UK) and left arm brachial blood pressure recorded 
using an ECGgated automated BP cuff (Tango, SunTech Medical, Eynsham, United 
Kingdom).  Resting HR and BP will be recorded following the 15minute rest period.  
 
+()
&,  
 


Respiratory gas exchange data will be collected using an Oxycon Pro (Jaeger, Hoechburg, 
Germany) breathbybreath metabolic cart. Calibration to ambient temperature, humidity, 
altitude and barometric pressure will be performed. Gas flowvolume will be calibrated using 
a 3L syringe and will be repeated on at least two occasions. Offset values are automatically 
calculated for accurate measurement of ventilatory volumes. Twopoint calibration, using 
known gas concentrations, will be performed to allow accurate quantification of inspired O2 
and expired CO2 concentrations (control gases: O2 16.4%; CO2 4.5%). The 12lead ECG will 
be measured continuously throughout the CPET.  An ECGgated automated BP will be 
monitored from the start of CPET and at the second minute of each exercise test stage until 
the end of the test.   
 
CPET will be conducted according to international recommendations 434547. A description of 
the CPET protocol, RPE scale, potential adverse symptoms and CPET stop procedures will 
be given to participants. The Modified Bruce Protocol48 will be used for all CPETs (Table 1).  
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Exercise tests will be preceded by a threeminute seated rest period to record pretest gas 
exchange, BP, and HR values. Patients will undertake CPET on a treadmill (General Electric 
[GR]) driven by a GE Case system (GE Healthcare, Buckinghamshire, UK).  Ventilatory 
expired gases will be collected continuously during the rest period, exercise and a sixminute 
recovery period.  Talking during CPET will be discouraged with the exception of reporting 
symptoms, asking to stop exercise, and to provide serial RPE scores. 
 
 
 
 
 
 
HR, RPE and estimated arterial oxygen saturation (SpO2) will be obtained after two and a 
half minutes of each test stage, at peak exercise and during the recovery period. Criteria for 
termination for CPET are displayed in Table 241.   
Data will be saved and exported for offline analysis. Data will be exported in 30 second, 15 
second and middle 5 of 7, breathbybreath averages. Table 3 provides a list of traditional 
and novel CPET variables.  
The primary outcome measure will be the change in VO2peak (mean VO2 over final 30 
seconds of a CPET). Secondary CRF outcome measures including the ventilatory anaerobic 
threshold (VAT), VE/VCO2 slope, peak O2 pulse (VO2/HR) and O2 uptake efficiency slope 
and plateaus (OUES and OUEP) will be assessed. 
 
 
 
 
 
 
 
 
 
 +  
-+.
  
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4 The modified Bruce protocol 
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ECG = Electrocardiogram; mmHg = Millimetres of Mercury; SpO2 = Peripheral Capillary O2 saturation 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Indications for exercise test termination 
Chest pain suggestive ischemia 
Ischemic ECG Changes (>2mm ST segment depression) 
Complex Ventricular Ectopy 
Second or third degree heart block 
Fall in systolic pressure 20 mmHg from highest value during the test 
Hypertension (250mmHg systolic; 120mmHg diastolic) 
Severe oxygen desaturation: SpO2 less than 80% when accompanied by symptoms and signs of 
severe hypoxemia 
Sudden pallor  
Loss of coordination 
Mental confusion 
Dizziness or faintness 
Signs of respiratory distress 
3 

– Exercise test termination criteria 
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VO2peak = Peak Oxygen Uptake; VO2 = Oxygen Uptake; CPET = Cardiopulmonary Exercise Test; DXA = Dual X-ray Absorptiometry; VE = Minute Ventilation; RER = 
Respiratory Exchange Ratio; VAT = Ventilatory Anaerobic Threshold; VCO2 = Carbon Dioxide Elimination; VE/VCO2 = Ventilatory Efficiency with Respect to CO2 
elimination; OUES; Oxygen Uptake Efficiency Slope; OUEP = Oxygen Uptake Efficiency Plateau; O2/HR Oxygen Pulse; CHD = Coronary Heart Disease; CHF = Chronic 
Heart Failure 
 
Variable Definition Significance 
Peak Oxygen 
Uptake 
(VO2peak) 
 
Mean VO2 over the last 30 seconds of CPET 
Reported in raw units (ml), adjusted for body mass 
(ml
.
kg
1.
min
1
) and lean body mass determined 
using DXA (ml
.
kg
1.
min
1
) 
Traditional definition of peak aerobic fitness and limit of 
cardiovascular function 
Indicative of cardiovascular disease severity, universal 
prognosticator 
Abnormal when below 85% of the predicted value 
 
Ventilatory 
Anaerobic 
Threshold 
(VAT)  
Determined using the Vslope method 
method using the middle 5 of 7 breath data 
averaging. 
Reported in raw units (ml), adjusted for body mass 
(ml
.
kg
1.
min
1
) and lean body mass determined 
using DXA (ml
.
kg
1.
min
1
). 
Represents the point above which, further increments in work rate 
are increasingly sustained through anaerobic metabolism. 
Objective marker of submaximal aerobic fitness/endurance.  A VO2  
at VAT between 40 and 60% VO2peak is considered normal 
 
Peak 
Respiratory 
Exchange Ratio 
(RER) 
The ratio of ventilated CO2 to O2 averaged over the 
last 30 seconds of CPET 
Reported in arbitrary units 
In conjunction with the attainment of one other marker of peak 
performance, RER of > 1.10 is indicative of a ‘peak’ effort during 
CPET 
VE/VCO2 slope The slope relationship between VCO2 (xaxis) and 
VE (yaxis) throughout the entire CPET 
Reported in arbitrary units 
Index of ventilatory efficiency representing the matching of ventilation 
and perfusion of the lungs and heart respectively, as well as 
peripheral chemoreceptor sensitivity 
Slope> 34 suggest poor prognosis 
 
Oxygen uptake 
efficiency slope 
(OUES) 
The slope relationship between the logarithmically 
transformed minute ventilation (xaxis) and VO2 (y
axis) throughout the entire CPET 
Reported in arbitrary units 
 
Index of ventilatory efficiency with strong correlation to VO2peak 
Slope <1.4 considered suggest poor prognosis 
High accuracy even when exercise tests are not maximal 
 
Oxygen uptake 
efficiency 
plateau 
(OUEP) 
The highest plateau in VO2 in relation to VE. 
Reported as the highest consecutive values of 
VO2/VE over 90 seconds. 
Indicates the efficiency of oxygen uptake and global cardiovascular 
function 
Can be used to profile severity of CHD and CHF with mean plateau 
values of 2030 (VO2/VE mL/L) for CHF phenotypes 
Low OUEP  (<65% predicted) prognostic  
Oxygen Pulse  
(O2/HR) 
The ratio of VO2 to HR (O2/HR) 
Values can be reported at a single point in time 
e.g. peak O2/HR averaged over 15 seconds or, 
plotted to demonstrate a response across an entire 
CPET 
Indirect measure of stroke volume response to exercise 
O2/HR plateau or reduction despite increases work rates, especially 
a lower to moderate work rates may indicate falling stroke volume 
and possible myocardial ischaemia/myocardial wall motion 
abnormality. 
Low O2 pulse (< 85% predicted) and early plateau/reduction in O2 
pulse  indicate poorer prognosis 
 
 
Table 3 – Cardiopulmonary Exercise Test Variables 
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Resting spirometry will be conducted using an Oxycon Pro. Patients will breathe into a 
mouth piece connected to the respiratory flow turbine of the metabolic cart.  Patients will be 
instructed to and breathe normally during resting tidal volume measurements (litres). Ten full 
breathing cycles will be observed to allow normalisation of the breathing pattern. Flow 
volume loops will be conducted to obtain forced spirometry measurements. Demonstration 
and instruction will be given prior to patients attempting the manoeuvre.  Up to eight flow
volume loops will be conducted to obtain three high quality manoeuvres. Acceptable 
reproducibility will be defined as ≤0.150 L difference between the largest and second largest 
forced expiratory volume in one second (FEV1) and forced vital capacity (FVC) 
measurements49.  FEV1, FVC and peak expiratory flow (PEF) will be recorded.  Maximum 
voluntary ventilation will be estimated (eMVV) using the calculation FEV1 x 40
5052.  
 
#(
54!)
3+ )
-#5.


Body composition will be analysed using DXA (Lunar iDXA, GE Healthcare, 
Buckinghamshire, UK). Body composition analysis will be performed by the Lunar iDXA’s 
integrated software.  Total body mass, total body fat, compartmental body fat, lean body 
mass and compartmental lean body mass will be recorded for this study. Total body mass 
will be used for the calculation of BMI.  
 
&

S trained echocardiograph technician will conduct each echocardiogram. Standard 
echocardiogram techniques will be used including 2D, Mmode, pulse wave Doppler to 
assess cardiac structure and function (systolic and diastolic). Left ventricular function will be 
determined from 2D echocardiography. Left ventricular function will be assessed by 
estimation on a scale of normal, mild, mildtomoderate, moderate, moderatetosevere, and 
severe. Left ventricular ejection fraction (LVEF) will be calculated using the Simpson’s 
formula from measurements of enddiastolic and endsystolic volumes on apical 4chamber 
and 2chamber views 2D views, following the guidelines of Schiller and colleagues53. LVSD 
will be diagnosed if LVEF is ≤45%. When LVEF cannot be calculated, LVSD will be 
diagnosed were LVEF ≤45 or there was at least “mildtomoderate” impairment. 
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CIMT will be measured using an automated ultrasound system (Panasonic CardioHealth 
Station, Panasonic Biomedical Sales Europe BV, Leicestershire, UK).  This system has low 
measurement variability in healthy and cardiac populations when investigations are 
conducted by experienced and inexperienced operator’s alike34 54. CIMT will be assessed 
using previously outlined methods34. Briefly, the CHS is equipped with a broadband probe 
(513 MHz) with a centre frequency optimised for carotid imaging. When correctly positioned 
over the CCA, automated integrated software locates the vessel’s far wall using a region of 
interest tool. The CHS automatically captures a sequence of images at enddiastole by 
monitoring vessel distension characteristics and ‘freezes’ when predefined CIMT boundary 
quality criteria are met. Multiple measurements taken from a 1cm segment of the CCA 
located 1cm proximally from the carotid bifurcation will be obtained. CIMT will be measured 
at the right anterior (150°), lateral (120°) and posterior (90°) aspects and on the left anterior 
(210°), lateral (230°) and posterior (270°) aspects. Mean and maximum (max) IMT will be 
recorded to three decimal places. Image quality will be manually inspected and trace lines 
modified where required. To enhance measurement reproducibility, the probe is equipped 
with an accelerometer and gyroscope that tracks the angle (˚) of insonation relative to 
ground. Each CIMT measurement is recorded with the angle that the image was taken. 


6
+ 

Blood samples will be drawn and placed in a refrigerated (4C) centrifuge at 3000 
revolutions per minute, for 15 minutes. Routine testing will include full blood cell count, total 
cholesterol, estimated LDL cholesterol, HDL cholesterol, Triglycerides), kidney (eGFR) and 
liver function tests, nonfasting glucose and, NTproBNP. Additional blood serum and 
plasma samples will be stored in a 80C freezer for future analysis of current and emerging 
biochemical markers of cardiovascular and metabolic health. 
 
& 
4( 
%)

A 5year risk of allcause mortality will be calculated for each patient using the  CALIBER 5
year prognostic risk score for stable CHD phenotypes (https://www.ucl.ac.uk/health
informatics/caliber)41. The CALIBER risk assessment model includes sociodemographics, 
CVD diagnosis and severity, CVD and nonCVD comorbidities, primary risk factors, 
psychosocial risk factors and plasma biomarkers.   
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Patients in the TG will undergo a routine eight week (twice weekly, 16 sessions) CR exercise 
programme. A physiotherapist will conduct a onetoone assessment before each patient 
commences exercise training.  A personal exercise prescription will be developed for each 
individual. Patients will be asked to selfmonitor exercise intensity and encouraged to 
maintain a HR corresponding to 4070% of their predicted heart rate reserve (HHR) or, an 
exercise ‘effort’ between “light” and “somewhat hard” (1114) on Borg’s ratings of perceived 
exertion55. Estimated training zones will be calculated using the Karvonan formula: 
((206  (0.7 x age)) – resting heart rate ( 30 if taking betablockers) 
Heart rate will be monitored with a Polar heart rate monitor. HR and RPE will be recorded at 
the end of each CV exercise station. This conforms to the recommendations of the 
Association of Chartered Physiotherapists in Cardiac Rehabilitation56 and the British 
Association of Cardiac Prevention and Rehabilitation57 58 (i.e., >20 min aerobic exercise at 
40–70% heart rate reserve). An example list of CV and active recovery (AR) exercises are 
displayed in Table 4. 
 
 
Cardiovascular circuit Exercises Active Recovery Exercises 
Box stepping Arm curls 
Static cycling Sit to stand 
Treadmill walking Wall pressup 
Concept II rower Leg curls 
Marching on the spot Lateral arm raises 
Knee raises Trunk rotation 
Half stars  
 
 
Each exercise circuit will consist of a structured eight or nine station programme 
incorporating CV and AR exercises. CV exercises will initially be prescribed for 
approximately 12 min duration and uptitrated for each session depending on HR and RPE 
responses. The target CV exercise duration for each session will be 20 minutes although CV 
exercise duration may be less than this in the first instance.  
 
 
Table 4 – Example cardiovascular and active recovery exercises  
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The primary end point for statistical analysis is the mean change in VO2 peak (mL
.kg1.min1) 
from visit 1 to visit 2. For statistical purposes, visit 3 will be treated as a followup.  This will 
establish the initial effect of the eightweek exercise intervention and any effects that it may 
have on CRF and cardiometabolic health over the 12month study period. A main effect and 
an interaction effect for VO2peak will be investigated using a general linear model (parametric 
approach). The number of patients achieving a VO2peak improvement greater than 0.5 and 
1.5 METs will also be reported24 26. These values correspond to improvements in CRF 
resulting from UK and international CR respectively. Changes in other CRF variables will be 
discussed within the context of clinically meaningful thresholds (Table 3).  Baseline VO2 peak, 
age, and the categorical covariate, gender will be entered as covariates in exploratory 
analysis. Significant differences in group characteristics identified at baseline will also be 
treated as covariates.Secondary outcome measures, including CIMT, and both maximal 
and submaximal CRF fitness measures will be evaluated using the same approaches and 
covariates as the primary outcome analysis. Continuous measures of exercise dose  will be 
used to predict changes to peak VO2peak and other CPET variables.
 
Data will be entered into SPSS by a single investigator who will maintain overall 
responsibility for data quality. The primary and secondary outcome analyses will be 
conducted at the conventional (twosided) 5% alpha level. Where parametric data 
distribution allows, partial eta squared values will also be reported. To reduce the risk of 
falsepositive claims, secondary analyses will be considered exploratory if nonsignificant 
results are obtained from the primary analysis. All analyses will be performed on an 
intentiontotreat basis. Analysis carrying the last observed values forward (baseline or 3
month outcomes) will be performed for patients lost to followup. A  analysis, will 
also be conducted. Patients completing at least 14 (out of 16) exercise sessions will be 
classed as having completed CR. No timeframe for completion will be imposed, as cardiac 
rehabilitation is typically extended to incorporate any missed exercise sessions. All data will 
be summarised and reported in accordance with the Consolidated Standards of Reporting 
Trials (CONSORT) guideline49.  
Power analysis, performed in GPower59 showed that 203 patients (total) would be needed 
to attain statistical significance between the two groups. This was based on an estimated 
post intervention between group (TG compared to CG) VO2peak difference of 2 ml
.kg1.min1 
with a pooled standard deviation of 4 ml.kg1.min1. 2 ml.kg1.min1 was selected based on a 
predicted 0.52 MET (ml.kg1.min1) CRF increase recently reported in UK CR programmes24. 
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A power of 90% and a group allocation ratio of 70% TG (123 participants) to 30% CG (80 
participants) and a predicted study attrition rate of 15% were applied. The assumption of 
uneven group sizes was made based on a local audit reporting that more patients participate 
in structured exercise than decline (TG 57%; CG 43%).  
Approximately 440 patients attend the local nurse led CR clinic each year. With a 
recruitment rate of 10%, (44 patients per year) the study duration is estimated to be 5 years. 
The first patient was recruited in March 2014 and recruitment is ongoing. The study is 
expected to complete in March 2019. A formal interim analysis60 on the primary and 
secondary outcomes will be conducted when 70 patients have completed the study (one 
third of the cohort required on the a priori determined sample size). A decision on trial 
progression will be collectively made by the research team (estimated to be January 2018). 
A data monitoring committee will not be used owing to the observational nature of the study. 
 

! 3
&,  
* +
) 
Recent evidence11 suggests that no single exercise component within CR is predictive of 
mortality outcomes. However, reductions in both total and cardiovascular mortality were 
reported in trials which reported high levels of participant exercise adherence compared to 
those recording lower levels11. Patients' exercise doses have also been related to longterm 
survival outcomes 61. Accordingly, all exercise training characteristics including adherence to 
the programme, will be recorded. CV exercise duration achieved by  each patient at each of 
their 16 CR sessions will be calculated and summed to report a total exercise training 
duration. To characterise exercise intensity during each exercise session, the mean of 
patients’ HR following completion of all CV exercises for each session will be calculated. 
Patients’ ‘mean peak HR’ for each exercise session willbe pooled for analysis. A ‘median of 
the mean’ HR will be reported. ‘Median peak HR’ will expressed as a percentage of the VAT 
determined from visit 1 CPET and relative to HRR obtained from visit 1 CPET. A simple 
composite score of intensity and CV exercise duration for each training session will be 
calculated and summed to provide an overall “exercise dose” for each participant. The 
composite score will be:  
 
 
As an additional marker of exercise intensity the mean of a patient’s RPE following 
completion of an exercise session will be calculated (mean RPE). As with HR, patient’s RPE 
scores for each exercise session will be pooled for analysis. 
Mean peak HR  
Patients’ CPET HRR  x   CV exercise duration 
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It is anticipated that throughout the trial, the experiences gained will be presented at national 
conferences and nonacademic outlets such as national governing body publications. On 
completion, the study results will be published in peerreviewed journals and presented at 
scientific meetings.  
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Figures  
 
Figure 1 – Study flow diagram 
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SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents* 
Section/item Item 
No 
Description Addressed on 
page number 
Administrative information 
 
Title 1 Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym 1 
Trial registration 2a Trial identifier and registry name. If not yet registered, name of intended registry Observational 
Study - Not 
Required 
2b All items from the World Health Organization Trial Registration Data Set  
Protocol version 3 Date and version identifier All Pages - Footer 
Funding 4 Sources and types of financial, material, and other support Not Funded 
Roles and 
responsibilities 
5a Names, affiliations, and roles of protocol contributors 1 & 2 
5b Name and contact information for the trial sponsor 1 
 5c Role of study sponsor and funders, if any, in study design; collection, management, analysis, and 
interpretation of data; writing of the report; and the decision to submit the report for publication, including 
whether they will have ultimate authority over any of these activities 
 
No role 
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 5d Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint 
adjudication committee, data management team, and other individuals or groups overseeing the trial, if 
applicable (see Item 21a for data monitoring committee) 
 
 
 
N/A 
Introduction    
Background and 
rationale 
6a Description of research question and justification for undertaking the trial, including summary of relevant 
studies (published and unpublished) examining benefits and harms for each intervention 
4 to 6 
 6b Explanation for choice of comparators 6 to 7 
Objectives 7 Specific objectives or hypotheses 5 to 6 
Trial design 8 Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), 
allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory) 
 
6 to 8 
Methods: Participants, interventions, and outcomes  
Study setting 9 Description of study settings (eg, community clinic, academic hospital) and list of countries where data will 
be collected. Reference to where list of study sites can be obtained 
6 (also Figure 1 
and page 8) 
Eligibility criteria 10 Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and 
individuals who will perform the interventions (eg, surgeons, psychotherapists) 
7 (echocardiogram 
on 11) 
Interventions 11a Interventions for each group with sufficient detail to allow replication, including how and when they will be 
administered 
Figure 1, Table 
1,2,3 and 4. Page 
8 to 14 
11b Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose 
change in response to harms, participant request, or improving/worsening disease) 
Page 13 - Interim 
power analysis 
11c Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence 
(eg, drug tablet return, laboratory tests) 
N/A - Assessment 
of routine care 
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11d Relevant concomitant care and interventions that are permitted or prohibited during the trial 7 
Outcomes 12 Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood 
pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, 
median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen 
efficacy and harm outcomes is strongly recommended 
 
Page 5 - relevance 
on page 4 and 5 
as well as Table 3 
Participant timeline 13 Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for 
participants. A schematic diagram is highly recommended (see Figure) 
Figure 1 
Sample size 14 Estimated number of participants needed to achieve study objectives and how it was determined, including 
clinical and statistical assumptions supporting any sample size calculations 
13 
Recruitment 15 Strategies for achieving adequate participant enrolment to reach target sample size 6 to 7 
Methods: Assignment of interventions (for controlled trials)  
Allocation:    
Sequence 
generation 
16a Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any 
factors for stratification. To reduce predictability of a random sequence, details of any planned restriction 
(eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants 
or assign interventions 
N/A 
Allocation 
concealment 
mechanism 
16b Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, 
opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned 
N/A 
Implementation 16c Who will generate the allocation sequence, who will enrol participants, and who will assign participants to 
interventions 
6 to 7 
Blinding (masking) 17a Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome 
assessors, data analysts), and how 
N/A 
 17b If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant’s 
allocated intervention during the trial 
N/A 
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Methods: Data collection, management, and analysis 
 
Data collection 
methods 
18a Plans for assessment and collection of outcome, baseline, and other trial data, including any related 
processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of 
study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known. 
Reference to where data collection forms can be found, if not in the protocol 
7 to 14 
 18b Plans to promote participant retention and complete follow-up, including list of any outcome data to be 
collected for participants who discontinue or deviate from intervention protocols 
N/A 
Data management 19 Plans for data entry, coding, security, and storage, including any related processes to promote data quality 
(eg, double data entry; range checks for data values). Reference to where details of data management 
procedures can be found, if not in the protocol 
13 
Statistical methods 20a Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the 
statistical analysis plan can be found, if not in the protocol 
13 
 20b Methods for any additional analyses (eg, subgroup and adjusted analyses) 13 to 14 
 20c Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any 
statistical methods to handle missing data (eg, multiple imputation) 
 
13 
Methods: Monitoring 
 
Data monitoring 21a Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of 
whether it is independent from the sponsor and competing interests; and reference to where further details 
about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not 
needed 
13 
 21b Description of any interim analyses and stopping guidelines, including who will have access to these interim 
results and make the final decision to terminate the trial 
13 
Harms 22 Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse 
events and other unintended effects of trial interventions or trial conduct 
8 
Auditing 23 Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent 
from investigators and the sponsor 
N/A 
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Ethics and dissemination  
Research ethics 
approval 
24 Plans for seeking research ethics committee/institutional review board (REC/IRB) approval 1 and 6 
Protocol 
amendments 
25 Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, 
analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial registries, journals, 
regulators) 
6 
Consent or assent 26a Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and 
how (see Item 32) 
8 
 26b Additional consent provisions for collection and use of participant data and biological specimens in ancillary 
studies, if applicable 
N/A 
Confidentiality 27 How personal information about potential and enrolled participants will be collected, shared, and maintained 
in order to protect confidentiality before, during, and after the trial 
7 
Declaration of 
interests 
28 Financial and other competing interests for principal investigators for the overall trial and each study site 1 
Access to data 29 Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that 
limit such access for investigators 
13 
Ancillary and post-
trial care 
30 Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial 
participation 
N/A 
Dissemination policy 31a Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, 
the public, and other relevant groups (eg, via publication, reporting in results databases, or other data 
sharing arrangements), including any publication restrictions 
3 and 14 
 31b Authorship eligibility guidelines and any intended use of professional writers Page 2 
 31c Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code N/A 
Appendices    
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Informed consent 
materials 
32 Model consent form and other related documentation given to participants and authorised surrogates Appendix 1 
Biological 
specimens 
33 Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular 
analysis in the current trial and for future use in ancillary studies, if applicable 
11 to 12 
*It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on the items. 
Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons 
“Attribution-NonCommercial-NoDerivs 3.0 Unported” license. 
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